The Europe Antibody Therapeutics Market would witness market growth of 14.0 % CAGR during the forecast period (2023-2030).
Antibody therapeutics have successfully treated autoimmune diseases by modulating the immune system's activity. In conditions such as rheumatoid arthritis, psoriasis, and lupus, monoclonal antibodies can target inflammatory cytokines or immune cells involved in the disease process. By dampening immune responses, these antibodies help alleviate symptoms and reduce the progression of autoimmune disorders. Antibody therapeutics have applications in hematological disorders, including thrombocytopenia and hemophilia. Monoclonal antibodies can target specific components involved in blood clotting or platelet production, providing therapeutic options for patients with bleeding disorders. Antibody therapeutics are under exploration for the treatment of neurological disorders, including Alzheimer's disease and multiple sclerosis. Monoclonal antibodies may target pathological proteins involved in neurodegenerative processes or modulate immune responses within the central nervous system to mitigate the progression of these disorders. In transplantation medicine, antibody therapeutics are used to prevent organ rejection.
The use of antibody therapies for respiratory conditions, including asthma and chronic obstructive pulmonary disease (COPD), is being explored. Monoclonal antibodies can target specific inflammatory pathways involved in these conditions, providing a targeted and personalized approach to managing respiratory diseases. Inflammatory bowel diseases, like Crohn's disease and ulcerative colitis, are among the gastrointestinal disorders where antibody therapeutics have demonstrated efficacy. Monoclonal antibodies can modulate immune responses in the gut, reducing inflammation and improving symptoms in patients with these chronic conditions. Antibody therapeutics treat dermatological conditions, including psoriasis and atopic dermatitis. Monoclonal antibodies targeting specific cytokines involved in skin inflammation help manage these disorders and improve patients' quality of life.
As per Destatis, 2020, since younger birth cohorts also show decreasing numbers of people, over 65-year-olds make up an ever-larger proportion of the total population over time. The very old group, above 85, is particularly fast growing. Their number increased from 1.2 million in 1991 to 2.4 million in 2019. Similarly, according to a report on the French aging policy published by the United Nations, as in other European countries, France faces a continuous and significant increase in older people: in 2012, there were 15 million people aged more than 60 years old in France. This number will reach 24 million in 2060. The factors mentioned above will drive the regional market growth.
The Germany market dominated the Europe Antibody Therapeutics Market by Country in 2022 and would continue to be a dominant market till 2030; thereby, achieving a market value of $41,487.8 million by 2030. The UK market is registering a CAGR of 13.1% during (2023 - 2030). Additionally, The France market would showcase a CAGR of 14.9% during (2023 - 2030).
Based on Route of Administration, the market is segmented into Intravenous, Subcutaneous, and Others. Based on Format, the market is segmented into, Monoclonal Antibody, Polyclonal Antibody Therapy, Bispecific Antibody, Antibody fragment & Others. Based on Source, the market is segmented into Human, Humanized, and Chimeric. Based on End User, the market is segmented into Hospitals, Long-term care facilities, and Others. Based on Disease Areas, the market is segmented into Autoimmune & Inflammatory Diseases, Neurology, Osteology, Hematology, Oncology, Infectious Diseases, Immunology, and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stakeholders of the market. Key companies profiled in the report include F. Hoffmann-La Roche Ltd, AbbVie, Inc., Johnson & Johnson (Johnson & Johnson Services, Inc.), Merck KGaA, Bristol Myers Squibb Company, AstraZeneca PLC, Sanofi S.A., Novartis AG, Biogen, Inc. and Amgen, Inc.
Antibody therapeutics have successfully treated autoimmune diseases by modulating the immune system's activity. In conditions such as rheumatoid arthritis, psoriasis, and lupus, monoclonal antibodies can target inflammatory cytokines or immune cells involved in the disease process. By dampening immune responses, these antibodies help alleviate symptoms and reduce the progression of autoimmune disorders. Antibody therapeutics have applications in hematological disorders, including thrombocytopenia and hemophilia. Monoclonal antibodies can target specific components involved in blood clotting or platelet production, providing therapeutic options for patients with bleeding disorders. Antibody therapeutics are under exploration for the treatment of neurological disorders, including Alzheimer's disease and multiple sclerosis. Monoclonal antibodies may target pathological proteins involved in neurodegenerative processes or modulate immune responses within the central nervous system to mitigate the progression of these disorders. In transplantation medicine, antibody therapeutics are used to prevent organ rejection.
The use of antibody therapies for respiratory conditions, including asthma and chronic obstructive pulmonary disease (COPD), is being explored. Monoclonal antibodies can target specific inflammatory pathways involved in these conditions, providing a targeted and personalized approach to managing respiratory diseases. Inflammatory bowel diseases, like Crohn's disease and ulcerative colitis, are among the gastrointestinal disorders where antibody therapeutics have demonstrated efficacy. Monoclonal antibodies can modulate immune responses in the gut, reducing inflammation and improving symptoms in patients with these chronic conditions. Antibody therapeutics treat dermatological conditions, including psoriasis and atopic dermatitis. Monoclonal antibodies targeting specific cytokines involved in skin inflammation help manage these disorders and improve patients' quality of life.
As per Destatis, 2020, since younger birth cohorts also show decreasing numbers of people, over 65-year-olds make up an ever-larger proportion of the total population over time. The very old group, above 85, is particularly fast growing. Their number increased from 1.2 million in 1991 to 2.4 million in 2019. Similarly, according to a report on the French aging policy published by the United Nations, as in other European countries, France faces a continuous and significant increase in older people: in 2012, there were 15 million people aged more than 60 years old in France. This number will reach 24 million in 2060. The factors mentioned above will drive the regional market growth.
The Germany market dominated the Europe Antibody Therapeutics Market by Country in 2022 and would continue to be a dominant market till 2030; thereby, achieving a market value of $41,487.8 million by 2030. The UK market is registering a CAGR of 13.1% during (2023 - 2030). Additionally, The France market would showcase a CAGR of 14.9% during (2023 - 2030).
Based on Route of Administration, the market is segmented into Intravenous, Subcutaneous, and Others. Based on Format, the market is segmented into, Monoclonal Antibody, Polyclonal Antibody Therapy, Bispecific Antibody, Antibody fragment & Others. Based on Source, the market is segmented into Human, Humanized, and Chimeric. Based on End User, the market is segmented into Hospitals, Long-term care facilities, and Others. Based on Disease Areas, the market is segmented into Autoimmune & Inflammatory Diseases, Neurology, Osteology, Hematology, Oncology, Infectious Diseases, Immunology, and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stakeholders of the market. Key companies profiled in the report include F. Hoffmann-La Roche Ltd, AbbVie, Inc., Johnson & Johnson (Johnson & Johnson Services, Inc.), Merck KGaA, Bristol Myers Squibb Company, AstraZeneca PLC, Sanofi S.A., Novartis AG, Biogen, Inc. and Amgen, Inc.
Scope of the Study
Market Segments Covered in the Report:
By Route of Administration- Intravenous
- Subcutaneous
- Others
- Monoclonal Antibody
- Polyclonal Antibody Therapy
- Bispecific Antibody
- Antibody fragment & Others
- Human
- Humanized
- Chimeric
- Hospitals
- Long-term care facilities
- Other
- Autoimmune & Inflammatory Diseases
- Neurology
- Osteology
- Hematology
- Oncology
- Infectious Diseases
- Immunology
- Others
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
Key Market Players
List of Companies Profiled in the Report:
- F.Hoffmann-La Roche Ltd
- AbbVie, Inc.
- Johnson & Johnson (Johnson & Johnson Services, Inc.)
- Merck KGaA
- Bristol Myers Squibb Company
- AstraZeneca PLC
- Sanofi S.A.
- Novartis AG
- Biogen, Inc.
- Amgen, Inc.
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market at a Glance
Chapter 3. Market Overview
Chapter 5. Europe Antibody Therapeutics Market by Route of Administration
Chapter 6. Europe Antibody Therapeutics Market by Format
Chapter 7. Europe Antibody Therapeutics Market by Source
Chapter 8. Europe Antibody Therapeutics Market by End User
Chapter 9. Europe Antibody Therapeutics Market by Disease Areas
Chapter 10. Europe Antibody Therapeutics Market by Country
Chapter 11. Company Profiles
Companies Mentioned
- F. Hoffmann-La Roche Ltd
- AbbVie, Inc.
- Johnson & Johnson (Johnson & Johnson Services, Inc.)
- Merck KGaA
- Bristol Myers Squibb Company
- AstraZeneca PLC
- Sanofi S.A.
- Novartis AG
- Biogen, Inc.
- Amgen, Inc.
Methodology
LOADING...
